- Top of page
- Key properties of IL-17 and Th17 cells to consider for clinical targeting
- Diseases with chronic inflammation and matrix destruction
- Other chronic inflammatory diseases
- Acute inflammatory diseases and infections
- Possible limitations of IL-17 targeting
- Supporting Information
The discovery of IL-17 and of the Th17 pathway has been a step in the classification of human diseases. Th17 targeting appears rather straightforward in diseases associated with inflammation and matrix destruction, such as rheumatoid arthritis, psoriasis, and Crohn's disease. In other conditions where IL-17 is expressed and Th17 activated, it is unclear whether this is a primary or secondary event, making the use of Th17 inhibitors less obvious.